Observational studyCardiovascular intervention and therapeutics2021
Late lumen enlargement after drug-coated balloon angioplasty for de novo coronary artery disease.
Observational study in Cardiovascular intervention and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04893291 (Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- A systematic review and meta-analysis of the use of drug-coated balloon angioplasty for treatment of both de novo and in-stent coronary chronic total occlusions.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Pooled it
- A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions.Cardiovascular drugs and therapy · 2022Trial
- Arterial remodeling and plaque changes after balloon angioplasty for de novo coronary lesions using DCB.Cardiovascular intervention and therapeutics · 2026Article
- Angiographic residual stenosis and clinical outcomes after elective drug-coated balloon angioplasty for de novo coronary lesions: a single center retrospective study.Cardiovascular intervention and therapeutics · 2026Article
- Revascularization with drug-coated balloons alone in complex coronary artery disease: a systematic review.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Feasibility and safety of only DCB approach in consecutive patients undergoing contemporary CTO PCI; the all-comers DCB study.Frontiers in cardiovascular medicine · 2026Article
- Superiority of coronary paclitaxel DCBs to limus DCBs in the late angiographic outcomes: the first meta-analysis showing the differences of coronary DCBs.Cardiovascular diagnosis and therapy · 2024Article
- Angiographic patterns after drug-coated balloon angioplasty for de novo coronary lesions.AsiaIntervention · 2024Article
- Cardiovascular Outcomes after Paclitaxel-Coated Balloon Angioplasty versus Drug-Eluting Stent Placement for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Feasibility of emergent reperfusion therapy using paclitaxel-coated balloons for acute coronary syndrome: lessons from the PEBSI Study.Cardiovascular diagnosis and therapy · 2023Article
- Drug Coated Balloon in the Treatment of De Novo Coronary Artery Disease: A Narrative Review.Journal of clinical medicine · 2023Review
- Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics.Cardiovascular intervention and therapeutics · 2023Review
- Randomized Pilot Study to Compare DCB-Based versus DST-Based Strategies for the Treatment of True or Complex Coronary Bifurcation Lesions.Reviews in cardiovascular medicine · 2023Article
- Establishment of a Nomogram for Predicting the Suboptimal Angiographic Outcomes of Coronary De Novo Lesions Treated with Drug-Coated Balloons.Advances in therapy · 2023Article
- The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome.Cardiology research and practice · 2023Article
- Delayed stenosis regression after drug-coated balloon angioplasty for femoropopliteal artery lesions.Heart and vessels · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to identify predictors of late lumen enlargement (LLE) after drug-coated balloon (DCB) angioplasty for de novo coronary lesions. LLE, which is defined as an increase in the luminal diameter of the vessel from the immediate postprocedural measurement to follow-up measurements, is frequently observed after DCB angioplasty for de novo coronary artery disease. No predictors of LLE are known. This retrospective observational study analyzed 196 de novo coronary lesions in 182 patients who underwent both DCB angioplasty and follow-up angiography. Of the 196 lesions, 109 (56%) developed LLE during a mean follow-up period of 7.2 ± 2.5 months. As defined by American College of Cardiology (ACC)/American Heart Association (AHA) lesion types, lesions with LLE were significantly less severe than lesions without LLE (types A, B1, B2 and C 15%, 35%, 38% and 13% vs. 7%, 24%, 45% and 24%, respectively; p = 0.036), although no significant differences in clinical or other lesion background characteristics were observed between the groups. Among type C lesions, chronic total occlusion (CTO) was more frequently observed in lesions with LLE than in lesions without LLE (79% vs 43%, p = 0.036). Lesion severity predicts LLE after DCB angioplasty for de novo coronary artery disease. Among type C lesions, CTO is expected in lesions showing LLE, and preparations should therefore be made prior to DCB application. Further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.